Global menu

Our global pages

Close
 
Dr. Tobias Maier, Partner

Dr. Tobias Maier

Partner

Rechtsanwalt, Co-Head of International Health and Life Sciences

Languages

German, English

Practice areas

  • Health and life sciences
  • Intellectual property
  • International trade
  • Litigation and dispute management
  • Media
  • Technology

Practice notes

Tobias Maier is a Partner in our Munich office and a member of our IP / Commercial group. He also co-heads our global sector group Health and Life Sciences.

Tobias is specialised advising German and international client in the area of Intellectual Property (IP) and Commercial Contracts (including R&D, technology transfer, licensing, distribution, cooperations). He advices his clients in the field of copyright, unfair competition, trade secrets and media law as well as reputation management. His clients are mainly from the life sciences, chemical, automotive, retail, media and consumer goods sector.

Tobias' contentious IP practice includes IP litigation with a focus on preliminary injunction proceedings and the protection and enforcement of the client's IP rights. His non-contentious intellectual property work includes advising clients on all kinds of commercial contracts relating to the creation, commercialisation and exploitation of IP rights. Tobias is further responsible for the development of strategies for international trade mark portfolios as well as the management and enforcement of national and international trade mark rights before various authorities and regular courts.

As global co-Head of our international Health & Life Sciences sector, he also focusses on advising national and international companies from the pharmaceutical, biotech and medical devices industries. In this context Tobias advices on clinical trials, technology agreements, R&D, licensing, contract research, IP collaborations as well as market entry and commercialisation strategies. He has a deep understanding of the regulatory requirements in this sector and also deals with healthcare compliance issues.

Tobias studied law at the University of Augsburg. He also worked for the legal cooperation office of the Deutsche Gesellschaft für Internationale Zusammenarbeit (GIZ) (German Society for International Cooperation) in Beijing within the framework of the Sino-German Rule of Law Dialogue. Afterwards, he wrote his PhD on Chinese law against unfair competition at the Max Planck Institute for Intellectual Property and Competition Law in Munich. Before he joined Eversheds Sutherland, Tobias worked for a US-American law firm in Munich.

Tobias is recommended for Healthcare law by Legal 500 Germany and WirtschaftsWoche. In addition, he is recognized by WirtschaftsWoche as a top lawyer for copyright law.

Tobias' recent experience includes advising:

  • A US-based tec giant on the market entry under CE-certification of a COVID-19 testing device in Europe
  • Otsuka on a licensing agreement with global pharmaceutical company Mylan to commercialize Deltyba™ (delamanid) for the treatment of adults with pulmonary multidrug-resistant tuberculosis (MDR-TB) in low- and middle-income countries
  • Owens & Minor on its sale of Movianto from a regulatory perspective (marketing authorisations and other licenses required)
  • An international generic drug company on the defence of marketing authorisations being challenged by the originator pharmaceutical company due to alleged IP infringements in the generics application
  • A German research institution on IP and regulatory related topics in collaborations and trial agreements with research companies
  • INEOS on the production of disinfectants in response to the COVID-19 crisis
  • US-based medical device manufacturer on IP-related topics in pre- and post-CE-marketing studies
  • Otsuka on the First-of-its-kind global Collaboration with the Gates Foundation and Johnson & Johnson, GSK and Evotec to develop transformative treatment regimens for tuberculosis
  • A medical devices distributor on marketing the Japanese parent company’s medical app to healthcare institutions in Europe, the Middle East and Africa
  • A European-based generics company on license agreements and collaborations
  • A US-based medical device manufacturer on the negotiations of agreements regarding clinical trials and post-CE-marketing studies with universities and other German research institutions
  • An international pharmaceutical company on legal matters in connection with market entry programmes by several national regulators regarding pharmaceuticals against an infectious disease
  • An international research company on R&D-collaborations and negotiations with research institutes and universities for the development and licensing of new technologies
  • Otsuka on a licensing agreement with Russian pharmaceutical company R-Pharm to commercialize Deltyba™ (delamanid) for the treatment of adults with pulmonary multidrug-resistant tuberculosis (MDR-TB) in the Russian Federation and the Commonwealth of Independent States (CIS)
  • A famous Italian jewellery company in relation to a trademark law infringement by a German producer of counterfeiting products
  • An internationally operating brand management and media company for children's and family entertainment on all media law matters in relation to its blockbuster TV series as well as on the acquisition of respective production shares therein from their co-production partner
  • An international automotive supplier concerning a high-volume cooperation with another automotive supplier in the areas of R&D and licensing
  • A South-African generics manufacturer in the area of medical products advertising law and parallel import of pharmaceuticals
  • Chinese solar companies on marketing measures in connection with their market entry and presence in Germany
  • A South African generics manufacturer against a competitor in connection with a dispute regarding an advertising campaign for its blockbuster product in the area of thrombosis treatment

Featured article

The Legal 500 -  The Clients Guide to Law Firms

The Legal 500 - The Clients Guide to Law Firms

 

The Legal 500 - The Clients Guide to Law Firms